Serum Stem Cell Growth Factor Beta for the Prediction of Therapy Response in Hepatocellular Carcinoma

Table 1

Clinical-pathological characteristics of the patients enrolled in the study.

	RF	TACE	TOTAL	p
Patients characteristics
Male / Female	11/4	11/3	22/7	ns
Age	72 ± 5	68 ± 10	70 ± 8	0.010
Etiologies	15	14	29	ns
Alcohol/metabolic	9	7	16
Alcohol	1	3	4
HCV	5	4	9
Clinical characteristics
CTP A/B	10/0	15/4	25/4	0.042
BCLC 0/A/B	2/10/3	2/5/7	4/15/10	ns
Milan criteria (in/out)	13/1	8/3	21/4 (unknown 4)	ns
Up-to-7 criteria (in/out)	14/0	9/2	23/2 (unknown 4)	ns
Largest nodule diameter (mm)	29 ± 10	27 ± 7	28 ± 9	ns
Total tumor volume (cm^3)	18 ± 24	22 ± 25	20 ± 24	ns
Laboratory finding
Creatinine (mg/dl)	0.9 ± 0.3	0.8 ± 0.2	0.9 ± 0.2	ns
Sodium (mmol/l)	136.0 ± 2.2	138.4 ± 2.6	138.0 ± 2.4	ns
Total bilirubin (mg/dl)	0.94 ± 0.33	1.33 ± 0.93	1.12 ± 0.68	0.033
Total protein (g/dl)	7.2 ± 0.5	7.4 ± 0.7	7.2 ± 0.6	ns
Albumin (g/dl)	3.8 ± 0.4	3.6 ± 0.3	3.7 ± 0.3	ns
AST (IU/l)	77.7 ± 79.7	46.7 ± 24.3	63.9 ± 62.5	0.001
ALT (IU/l)	80.3 ± 96.7	37.4 ± 19.4	61.2 ± 75.3	0.001
ALP (IU/l)	101.3 ± 44.1	101.8 ± 40.7	101.5 ± 41.8	ns
GGT (IU/l)	112.4 ± 109	135.3 ± 146.5	123.4 ± 126.7	ns
WBC (10^3/μl)	5.1 ± 2.1	4.8 ± 2.1	4.97 ± 2.07	ns
Hemoglobin (g/dl)	13.5 ± 2.1	13.7 ± 1.5	13.6 ± 1.8	ns
Hematocrit (%)	40.4 ± 5.7	40.6 ± 4.3	40.5 ± 4.9	ns
Platelets (10^3/μl)	135.7 ± 80	102.6 ± 55.3	119.7 ± 70.2	ns
AFP (ng/ml)	20 ± 30.7	18.5 ± 23.3	19.3 ± 26.8	ns
INR	1.12 ± 0.1	1.18 ± 0.1	1.14 ± 0.12	ns

HCV: hepatitis C virus, CTP: Child-Turcotte-Pugh, BCLC: Barcelona Clinic Liver Cancer, AST: aspartate aminotransferase, ALT: alanine aminotransferase, ALP: alkaline phosphatase, GGT: gamma glutamyl transferase, WBC: white blood cells, AFP: alpha fetoprotein, INR: international normalized ratio, and ns: not significant